Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial.
Diabetes
Dietary assessment tools
Feeding trial
Monounsaturated fats
Nutritional epidemiology
Olive oil
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
29 09 2023
29 09 2023
Historique:
received:
24
07
2023
accepted:
15
09
2023
medline:
2
10
2023
pubmed:
30
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes. Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639.
Sections du résumé
BACKGROUND
Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet.
METHODS
PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes.
RESULTS
Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results.
CONCLUSIONS
Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639.
Identifiants
pubmed: 37775736
doi: 10.1186/s12933-023-01994-2
pii: 10.1186/s12933-023-01994-2
pmc: PMC10542699
doi:
Substances chimiques
Olive Oil
0
Banques de données
ISRCTN
['ISRCTN35739639']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
262Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK102896
Pays : United States
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Med. 2014 Jul 24;12:112
pubmed: 25055810
Eur J Nutr. 2022 Jun;61(4):1735-1748
pubmed: 35001218
BMJ. 2019 Jul 03;366:l2368
pubmed: 31270064
Arch Intern Med. 2009 Apr 27;169(8):798-807
pubmed: 19398692
J Nutr. 2011 Jun;141(6):1140-5
pubmed: 21508208
N Engl J Med. 2018 Jun 21;378(25):e34
pubmed: 29897866
Nutr J. 2021 Mar 12;20(1):24
pubmed: 33712009
Nutr Metab Cardiovasc Dis. 2014 Sep;24(9):929-39
pubmed: 24787907
Nutrients. 2020 Sep 27;12(10):
pubmed: 32992649
Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 01;2(1):49-59
pubmed: 30225432
J Clin Endocrinol Metab. 2011 Jun;96(6):1654-63
pubmed: 21602457
Eur J Epidemiol. 2017 May;32(5):363-375
pubmed: 28397016
Nutrients. 2021 Apr 15;13(4):
pubmed: 33920947
BMJ. 2008 Jun 14;336(7657):1348-51
pubmed: 18511765
Lancet. 2019 Feb 2;393(10170):434-445
pubmed: 30638909
Clin Nutr. 2022 Dec;41(12):2659-2682
pubmed: 36343558
Eur J Epidemiol. 2011 Nov;26(11):877-86
pubmed: 22041998
Cardiovasc Diabetol. 2022 Sep 20;21(1):189
pubmed: 36127725
Lancet. 2014 Jun 7;383(9933):1999-2007
pubmed: 24910231
N Engl J Med. 2008 Jul 17;359(3):229-41
pubmed: 18635428
Mol Nutr Food Res. 2021 Jan;65(1):e1901290
pubmed: 32529753
Nutr Metab Cardiovasc Dis. 2023 Apr;33(4):724-736
pubmed: 36842958
N Engl J Med. 2017 Oct 5;377(14):1391-1398
pubmed: 28976864
Clin Investig Arterioscler. 2023 May-Jun;35(3):105-114
pubmed: 36184301
Int J Epidemiol. 2012 Apr;41(2):377-85
pubmed: 21172932
Am J Clin Nutr. 2021 Dec 1;114(6):1873-1885
pubmed: 34515299
Ann Intern Med. 2014 Jan 7;160(1):1-10
pubmed: 24573661
J Nutr Biochem. 2010 Apr;21(4):285-9
pubmed: 19369051
N Engl J Med. 2012 Oct 4;367(14):1373-4
pubmed: 23034044
J Nutr. 2017 Jun;147(6):1174-1182
pubmed: 28424256
JAMA. 2009 Jul 8;302(2):179-88
pubmed: 19584347
Adv Nutr. 2015 Jan 15;6(1):5-18
pubmed: 25593140
Adv Nutr. 2022 Oct 2;13(5):1787-1798
pubmed: 35472102
Br J Nutr. 2022 Oct 14;128(7):1371-1392
pubmed: 34289917
Nutrients. 2020 Sep 06;12(9):
pubmed: 32899917
Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e000094
pubmed: 32762254
Am J Med. 2016 Apr;129(4):407-415.e4
pubmed: 26721635
Diabetes Care. 2014 Jul;37(7):1824-30
pubmed: 24722497
J Am Diet Assoc. 2008 Jul;108(7):1134-44; discussion 1145
pubmed: 18589019
Cardiovasc Diabetol. 2021 Jan 5;20(1):5
pubmed: 33402187
Am J Clin Nutr. 2021 Apr 6;113(4):960-971
pubmed: 33471083
Rev Endocr Metab Disord. 2020 Sep;21(3):315-327
pubmed: 32829455
Eur Heart J. 2020 Jul 21;41(28):2645-2656
pubmed: 32406924
BMC Cancer. 2017 May 18;17(1):341
pubmed: 28521737
PLoS One. 2012;7(8):e43134
pubmed: 22905215
Diabetes Care. 2011 Sep;34(9):1913-8
pubmed: 21788627
Diabetes Care. 2011 May;34(5):1150-6
pubmed: 21464460